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he p38 mitogen–activated protein kinase (p38) is
activated in response to environmental stress and
inﬂammatory cytokines. Although several growth
factors, including ﬁbroblast growth factor (FGF)-2, mediate
activation of p38, the consequences for growth factor–
dependent cellular functions have not been well deﬁned.
We investigated the role of p38 activation in FGF-2–induced
angiogenesis. In collagen gel cultures, bovine capillary
endothelial cells formed tubular growth-arrested structures
in response to FGF-2. In these collagen gel cultures, p38
activation was induced more potently by FGF-2 treatment
compared with that in proliferating cultures. Treatment
with the p38 inhibitor SB202190 enhanced FGF-2–induced
tubular morphogenesis by decreasing apoptosis, increasing
T
 
DNA synthesis and cell proliferation, and enhancing the
kinetics of cell differentiation including increased expression
of the Notch ligand Jagged1. Overexpression of dominant
negative mutants of the p38-activating kinases MKK3 and
MKK6 also supported FGF-2–induced tubular morphogen-
esis. Sustained activation of p38 by FGF-2 was identiﬁed in
vascular endothelial cells in vivo in the chick chorioallantoic
membrane (CAM). SB202190 treatment enhanced FGF-2–
induced neovascularization in the CAM, but the vessels
displayed abnormal features indicative of hyperplasia of
endothelial cells. These results implicate p38 in organization
of new vessels and suggest that p38 is an essential regulator
of FGF-2–driven angiogenesis.
 
Introduction
 
Angiogenesis, the formation of capillaries from preexisting
vessels, plays a central role in a variety of physiological and
pathological conditions (Folkman, 1995; Risau, 1997).
Angiogenesis can be divided into a series of temporally
regulated events involving proteolytic digestion of the ex-
tracellular matrix, proliferation and migration of endothelial
cells, formation of functional capillaries, and remodeling of
the vascular bed through apoptosis. Several growth factors,
such as fibroblast growth factor (FGF)*
 
 
 
and vascular endo-
thelial growth factor (VEGF), initiate these events. Mitogen-
activated protein kinases (MAPKs) are common participants
in growth factor–induced signal transduction pathways from
the membrane to the nucleus. Activated MAPKs are known
to regulate the activities of transcription factors or kinases
further downstream by phosphorylation and thereby control
gene expression and cellular function. Prior to this study,
three major classes of MAPKs have been identified in mam-
malian cells including extracellular signal–regulated kinase
(ERK), c-jun NH
 
2
 
-terminal kinase (JNK), and p38 mitogen-
activated protein kinase (p38) (Waskiewicz and Cooper,
1995). It is well established that ERK is activated by most
growth factors in various types of cells of consequence for
cell proliferation and differentiation. In contrast, it is generally
considered that JNK and p38 are activated by environ-
mental stress, bacterial lipopolysaccharide, and inflamma-
tory cytokines (Kyriakis and Avruch, 1996). Although
many JNK and p38 activation stimuli are proapoptotic,
the biological outcome of their activation is highly diver-
gent and appears to be largely dependent on the cell type
or cellular context.
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Recent studies have demonstrated that p38 is also acti-
vated by several growth factors including FGF-2 (Ono and
Han, 2000). In certain types of cells, FGF-2 activates p38
and its downstream target MAPK-activated protein kinase-2
via a Ras-dependent pathway, which ultimately leads to
transcriptional activation of cyclic AMP response element-
binding protein and activating transcription factor (ATF)-2
(Tan et al., 1996; Xing et al., 1996). MKK3 and MKK6 are
relatively specific upstream regulators of p38 (Ono and Han,
2000). To date, four isoforms of the p38 family, namely
p38
 
 
 
, p38
 
 
 
, p38
 
 
 
, and p38
 
 
 
, have been identified; these
are encoded by distinct genetic loci but share a common
Thr-Gly-Tyr motif in kinase subdomain VIII (Ono and
Han, 2000).
In this report, we describe the role of p38 activation in
FGF-2–induced angiogenesis. We present evidence that
p38 activity is induced by FGF-2 in endothelial cells in
vivo and that p38 negatively regulates endothelial cell dif-
ferentiation by decreasing the expression of differentia-
tion-specific proteins such as the Notch ligand Jagged1.
Inhibition of p38 function leads to increased vessel for-
mation, but a large proportion of the vessels appeared
nonfunctional.
 
Results
 
FGF-2 induced tubular morphogenesis in bovine 
capillary endothelial cells
 
Tubular morphogenesis of primary endothelial cells in
three-dimensional collagen gels involves differentiation of
the cells to form vessel-like structures. Cells in the tubular
structures are growth arrested (Folkman and Haudenschild,
1980; Kubota et al., 1988; Ingber and Folkman, 1989),
which allows analysis of differentiation-specific events. In
agreement with previous studies (Montesano et al., 1983;
Folkman et al., 1989) FGF-2–treated bovine capillary endo-
thelial (BCE) cells cultured in collagen gels underwent tu-
bular morphogenesis with dramatic changes in cell mor-
phology (Fig. 1, A–H) compared with cell cultured on
gelatin-coated dishes (Fig. 1 I). FGF-2 is a well-established
potent inducer of tubular morphogenesis (Montesano et al.,
1986; Sato et al., 1991; Pepper et al., 1992). We examined the
Figure 1. FGF-2–dependent induction and regression of tubular morphogenesis in collagen gel cultures. (A–G) Kinetics of FGF-2–induced 
tubular morphogenesis of BCE cells cultured in collagen gels. After 16 h of serum starvation, BCE cells were seeded between two layers of 
collagen gels and stimulated with 10 ng/ml FGF-2. Photographs were taken at 1 (A), 3 (B), 16 (C), 24 (D), 48 (E and G), and 72 h (F) after onset 
of stimulation. Arrowheads in C indicate fusion of endothelial cell bodies. Arrowheads in G indicate capillary lumen observed as a translucent 
slit within the tubules. (H) DNA staining of BCE cells undergoing tubular morphogenesis. FGF-2–stimulated BCE cell cultures in collagen 
were incubated for 48 h, fixed, and stained with Hoechst 33342. The arrow and the arrowhead indicate hypercondensed and fragmented 
nuclei, respectively. (I) Morphology of BCE cells cultured on a gelatin-coated dish for 24 h. Bars, 100  m. 
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time course of tubular morphogenesis of BCE cells treated
with 10 ng/ml FGF-2. Initially, cells aggregated and ex-
tended fine branches (Fig. 1 A), and by 3 h the branches
started to connect (Fig. 1 B). Subsequently, by 16 h cells
lined up along the branches and fused (Fig. 1 C, arrow-
heads) and became organized in tube-like structures by 24 h
(Fig. 1 D). Between the 24- and 48-h time periods, capillary
lumen were formed and observed as translucent slits within
the tubules (Fig. 1 G, arrowheads) as described in previous
reports (Ingber and Folkman, 1989; Montesano et al.,
1991). By 48 h, cultures started to collapse and tubes even-
tually dissolved (Fig. 1 E). Cells released from dissolved
tubes exhibited morphologic features characteristic of apop-
tosis, including cell rounding, membrane blebbing, and cell
shrinkage, and displayed hypercondensed (Fig. 1 H, arrow)
and fragmented (Fig. 1 H, arrowhead) nuclei when stained
with Hoechst 33342. Tubes disappeared completely after an
 
 
 
72-h incubation (Fig. 1 F). Addition of fresh growth fac-
tor did not prevent regression of the tubes. Tubular mor-
phogenesis in the basal condition in the absence of FGF-2
was very rare. Thus, the tubular structures were regulated by
a balance between FGF-induced differentiation and regres-
sion/apoptosis. The tubular structures were induced by
FGF-2 at concentrations from 5 ng/ml, and maximal induc-
tion of tubular morphogenesis was seen at 
 
 
 
10–30 ng/ml
FGF-2 in agreement with previous studies (Montesano et
al., 1986; Pepper et al., 1992).
 
FGF-2 activates p38 in collagen gel cultures
 
We next addressed the question whether p38 was activated by
FGF-2 and VEGF in BCE cells. FGF-2 stimulation increased
p38 activity transiently in proliferating BCE cells cultured on
gelatin as measured by phosphorylation of ATF-2 (Fig. 2 A).
In the FGF-2–treated differentiating cells undergoing tubular
morphogenesis on collagen gels, p38 activity was increased
10-fold (Fig. 2 B; quantified in Fig. 2 C). As expected, p38
was strongly activated by hyperosmolar stress (300 mM
NaCl) in both types of culture (Fig. 2, A and B). Stimulation
with VEGF at different concentrations maximally induced
p38 activity 2.2-fold in the collagen gel culture (Fig. 2 B).
The pyridynyl imidazole derivatives SB202190 and
SB203580 have been shown to be highly selective inhibitors
of p38 activity (Lee et al., 1994; Cuenda et al., 1995; Jiang
et al., 1996) with no effect on the activity of ERK, JNK, or
other protein kinases. They inhibit the enzymatic activity of
p38 by competing with ATP for binding to p38 (Young et
al., 1997). Of the four described p38 isoforms, 
 
 
 
, 
 
 
 
, and 
 
 
 
appear to be sensitive to inhibition by SB202190 (Li et al.,
1996; Jiang et al., 1997). Indeed, addition of 10 
 
 
 
M
SB202190 to the in vitro kinase assay inhibited both FGF-
2– and NaCl-induced activation of p38 in BCE cells (Fig. 2
D), whereas addition of SB202474, an inactive structural
analogue of SB203580 (Lee et al., 1994), had no effect. We
employed these compounds to examine how p38 activation
affects FGF-2–induced tubular morphogenesis.
 
Inhibition of p38 activation enhances FGF-2–induced 
tubular morphogenesis
 
We examined the consequence of inhibition of p38 activity for
FGF-2–induced tubular morphogenesis in BCE cells cultured
in collagen gels. After a 16-h serum starvation, BCE cells were
cultured between collagen gels and treated or not with FGF-2
in the presence or absence of 10 
 
 
 
M SB202190. Tubular mor-
phogenesis was enhanced by treatment with SB202190 in an
FGF-2–dependent manner (Fig. 3, A and B). Thus, in cultures
treated with both FGF-2 and SB202190 for 24 h an increased
number of cells were engaged in tube formation, and there was
Figure 2. FGF-2 effectively activates p38 in collagen gel cultures. 
(A and B) BCE cells cultured on gelatin-coated dishes (A) or on collagen 
gels (B) were serum starved and treated or not with 50 ng/ml FGF-2 
or 100 ng/ml VEGF for 5–60 min or with 300 mM NaCl for 30 min. 
After treatment, cells were lysed, immunoprecipitated using the 
anti-p38 antibody, and analyzed by ATF-2 phosphorylation in vitro 
(top). Aliquots of lysates were analyzed by immunoblotting with the 
anti-p38 antibody (bottom). (C) Quantification of the p38 activity
induced by FGF-2 stimulation in A and B. (D) p38 activity was
induced in BCE cells by treatment with FGF-2 for 5 min or with NaCl 
for 30 min. Cells were lysed, immunoprecipitated with the anti-p38 
antibody, and the precipitates were preincubated with 10  M 
SB202190, a p38 inhibitor, or 10  M SB202474, an inactive com-
pound, followed by ATF-2 phosphorylation in vitro (top). Aliquots of 
the lysates were analyzed for equal loading of p38 (bottom). 
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an overall increase in tube length (for quantification see Fig. 3
B). By 72 h, the tubular structures had regressed in the FGF-
2–treated cultures, whereas cultures treated with FGF-2 to-
gether with SB202190 still contained tubular structures of
considerable length. The enhancing effect was dose dependent
at concentrations from 0.5 to 10 
 
 
 
M of SB202190 (Fig. 3 C).
Similar results were obtained when cells were treated with
SB203580, another inhibitor of p38 (unpublished data). In
contrast, the inactive compound SB202474 had no effect (Fig.
3 B). These findings indicate that inhibition of p38 activation
enhances FGF-2–induced tubular morphogenesis.
To exclude the possibility of any unspecific effects of the
SB202190 treatment on FGF-2–induced tubular morpho-
genesis, BCE cells were transiently cotransfected with cDNA
constructs encoding MKK3 and MKK6, MAPK kinases
which specifically phosphorylate p38. MKK3 and MKK6
are activated by dual phosphorylation on Ser-189/Thr-193
and Ser-207/Thr-211, respectively. Dominant negative ver-
sions of MKK3 and MKK6 were constructed by replacing
these phosphorylation sites with alanine residues as de-
scribed previously (Raingeaud et al., 1996). Expression of
the dominant negative MKK3/6 caused a 1.9-fold increase
in the total tube length at 24 and 48 h of incubation and an
18.3-fold increase at 72 h compared with the vector control
(Fig. 4, A and B), effects similar to those seen in the
SB202190-treated cultures. In contrast, expression of wild-
type MKK3/6 resulted in a suppressed tubular morphogene-
sis with an increase in the number of apoptotic cells.
The level of p38 activity in the transfected cells was ana-
lyzed under basal and FGF-2–stimulated conditions. In the
empty vector-transfected cells, increased activation of p38
was detected in the collagen gel cultures from 6 to 48 h in-
cubation (Fig. 4 C), whereas no activation was detected in
the gelatin cultures in spite of the continued high expression
level of p38. Expression of wild-type MKK3/6 slightly (1.5-
fold at 24 h incubation) enhanced the level of activated p38,
whereas dominant negative MKK3/6 clearly inhibited p38
activation in the collagen gel culture (Fig. 4 C). Due to the
regression of the tubes and apoptosis of the cells, the expres-
sion levels of p38 declined with time in these cultures.
FGF-2 treatment of BCE cells overexpressing wild-type
MKK3/6 slightly (1.3-fold) increased the level of activated
p38, whereas cells expressing dominant negative MKK3/6
failed to respond to FGF-2 with increased p38 activity (Fig.
Figure 3. SB202190 treatment enhances FGF-2–
induced tubular morphogenesis. (A and B) BCE cell 
collagen gel cultures were pretreated for 1 h with 10 
 M SB202190 or 10  M SB202474 and then treated or 
not with 10 ng/ml FGF-2. The cells were photographed 
after 24, 48, and 72 h of incubation (A). Total length of 
tubular structures from three fields ( 10 objective) per 
well was measured using NIH image software (B). 
Treatment with FGF-2 and SB202190 demonstrated 
marked increases in the total tube length from 24 to
72 h. Similar results were obtained in five independent 
experiments. Asterisks indicate significantly different 
from FGF-2 or FGF-2   SB202474 at p   0.05 
(unpaired Student’s t test). (C) Dose response effect of 
SB202190 on FGF-2–induced tubular morphogenesis 
was measured at 24 h of incubation. Each bar shows 
the mean   SD of duplicate wells. Bars, 100  m. 
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4 D, top). Expression of exogenous MKK3/6 was confirmed
by immunoblotting using anti-hemagglutinin (HA) mono-
clonal antibody; the expression of MKK3 clearly exceeded
that of MKK6 (Fig. 4 D, bottom). Taken together, these
data strongly support the notion that p38 activation exerts a
negative regulatory role in tubular morphogenesis.
 
SB202190 treatment directly enhances FGF-2–induced 
cell differentiation as indicated by expression of 
Jagged1 during tubular morphogenesis
 
Recent studies have shown that p38 plays an essential role in
cell differentiation in several different cell types (Engelman et
al., 1998; Morooka and Nishida, 1998; Zetser et al., 1999).
To examine the effect of p38 inhibition on endothelial cell
differentiation, we first compared the cell morphology after
8 h of incubation in collagen gel cultures treated with FGF-2
alone and those treated with a combination of FGF-2 and
SB202190. At that stage, cells treated with FGF-2 alone were
connected by thin extensions (Fig. 5 A, left). In cultures
treated with both FGF-2 and SB202190, cell bodies had
fused in a majority of cells in the culture (Fig. 5 A, right, ar-
rowheads). As shown in Fig. 1 C, fusion of endothelial cell
bodies was induced by FGF-2 alone only after 16 h.
Several studies have demonstrated that Notch signaling is
required for angiogenic vascular remodeling (Xue et al.,
Figure 4. Overexpression of dominant negative MKK3/6 
enhances FGF-2–induced tubular morphogenesis. BCE cells were 
transiently transfected with 3  g wild-type HA-MKK3 and 3  g 
wild-type HA-MKK6 (WT MKK3/6) or 3  g dominant negative 
HA-MKK3 and 3  g dominant negative HA-MKK6 (MKK3/6 [Ala]) 
or alternatively 6  g empty vector (Mock). At 24 h after transfection, 
the cells were seeded between two layers of collagen gels and 
treated with 10 ng/ml FGF-2. (A) Morphology of the cells after 24 h 
of stimulation. (B) Total length of tubular structures was measured as 
described in the legend to Fig. 3 B. Each bar shows the mean   SD 
of two independent experiments. (C) The transfected BCE cells 
cultured on gelatin-coated dishes or on collagen gels were lysed, 
and then p38 activity and protein levels of p38 were measured as 
described in the legend to Fig. 2. (D) At 24 h after transfection, 
the cells were serum starved for 16 h and treated or not with 50 
ng/ml FGF-2 for 5 min. The cells were then lysed, and p38 activity 
was measured (top). One part of the cell lysates was immunoblotted 
with anti-p38 antibody (middle) or anti-HA mAb (bottom). 
Bars, 100  m.
Figure 5. SB202190 treatment increases the kinetics of FGF-2–
induced cell differentiation. (A) BCE cell collagen cultures were 
preincubated for 1 h with 10  M SB202190 (right) or 0.1% DMSO 
(left) followed by treatment with 10 ng/ml FGF-2. The cells were 
photographed after 8 h of incubation. Arrowheads indicate fused 
cell bodies. (B) BCE cell cultures on collagen gels or on gelatin-
coated dishes were pretreated for 1 h with 10  M SB202190 or 
0.1% DMSO followed by treatment with 10 ng/ml FGF-2 and 
extraction at various time points with SDS sample buffer. Samples were 
immunoblotted with anti-Jagged1 antibody. The degree of Jagged1 
expression was quantified by NIH Image software. Each bar shows 
the mean   SD of three independent experiments. Bars, 100  m. 
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1999; Krebs et al., 2000; Uyttendaele et al., 2001) and
Jagged1, a ligand for its transmembrane receptor Notch, has
been implicated in the regulation of endothelial cell differen-
tiation in vitro (Zimrin et al., 1996; Uyttendaele et al.,
2000). We next tested the possibility that the FGF-2–
induced p38 pathway regulates endothelial cell differentiation
via modulating expression of Jagged1. Expression of Jagged1
increased in collagen gel cultures between the 8- and 48-h
time points (Fig. 5 B). The induction was specific for the full-
length 150-kD form of Jagged1. In contrast, expression of
Jagged1 was low and did not increase in the FGF-2–
treated proliferating gelatin-seeded culture. Treatment with
SB202190 in the presence of FGF-2 enhanced the expression
of Jagged1 in the collagen gel cultures (a 2.3-fold increase
from basal expression at the 24-h time point) compared with
that with FGF-2 alone (a 1.2-fold increase from basal expres-
sion at the 24-h time point). These results support the notion
that p38 negatively regulates differentiation of the endothelial
cells. Moreover, it is possible that Jagged1/Notch signaling is
involved in this regulatory pathway.
 
SB202190 treatment affects apoptosis, DNA synthesis, 
and proliferation during tubular morphogenesis
 
It is known that p38 regulates apoptotic cell death in response
to cellular stress or certain inflammatory cytokines (Kyriakis
and Avruch, 1996). We determined the extent of apoptosis in
FGF-2–treated BCE cell cultures in collagen gels in the pres-
ence or absence of SB202190 by staining with Hoechst
33342. Cells released from dissolved tubes displayed hyper-
condensed and fragmented nuclei, hallmarks of apoptosis
(Fig. 1 H). Quantitation of apoptotic cells showed that endo-
thelial cell cultures underwent massive apoptosis in the ab-
sence of growth factors during the first 24 h of culture (Fig. 6
A); in the presence of FGF-2, 20% of the cells were apoptotic.
There was no effect of the FGF-2 plus
 
 
 
SB202190 treatment
compared with FGF-2 alone at 24 h, but at 48 h cells treated
with FGF-2 in combination with SB202190 were protected
from apoptosis. Treatment with SB202190 alone had a mar-
ginal anti-apoptotic effect, probably depending on the endog-
enous production of growth factors. The exposure of phos-
phatidylserine on the outer leaflet of the plasma membrane
serves as a sensitive marker for early stages of apoptosis (Mar-
tin et al., 1995). To determine whether decreased apoptosis
contributed to the early effect of SB202190 in promotion of
tubular morphogenesis, exposed phosphatidylserine was de-
tected by use of fluorescein-conjugated annexin V. As shown
in Fig. 6 B, the percentage of annexin V–positive cells was not
affected by FGF-2 plus SB202190 treatment compared with
FGF-2 alone or FGF-2 plus SB202474 treatment at 8 and
24 h when FGF-2–induced tubular morphogenesis was modu-
lated by SB202190 treatment. In contrast, treatment with
FGF-2 and SB202190 significantly inhibited an increase in
annexin V–positive cells at 48 h. These results indicate that
FGF-2 regulates cell survival through activation of p38 during
the late phase of tubular morphogenesis but that early effects
of SB202190 treatment leading to increased tube length are
independent of inhibition of apoptosis.
The decreased apoptosis in the SB202190-treated cultures
was accompanied by increased DNA synthesis and cell prolif-
eration. Fig. 7, A and B, shows that the relative number of
BrdU-positive cells, indicative of S-phase entry, was 1.2% in
the FGF-2–treated collagen gel cultures. This proportion in-
creased to 13.2% in cultures treated with both FGF-2 and
SB202190 for 24 h. Control cultures receiving FGF-2 to-
gether with SB202474, or SB202190 alone, did not show an
increased number of BrdU-positive cells (Fig. 7 B). The effect
of SB202190 treatment on endothelial cell proliferation dur-
ing 3 d in collagen culture was assessed. As shown in Fig. 7 C,
the number of cells decreased in control cultures and in cul-
tures treated individually with FGF-2 or SB202190. This is in
agreement with previous reports that cell proliferation is ar-
rested during tubular morphogenesis (Folkman and Haudens-
child, 1980; Kubota et al., 1988; Ingber and Folkman, 1989).
Cultures treated with a combination of FGF-2 and SB202190
showed a slight increase in cell number on day 1 and 2. The
Figure 6. Apoptosis in differentiating endothelial cells treated 
with FGF-2 and SB202190. (A) BCE cell collagen cultures were 
pretreated or not with 10  M SB202190 or 10  M SB202474 for
1 h followed by stimulation or not with 10 ng/ml FGF-2. The cells 
were fixed and stained with Hoechst 33342 at 24, 48, and 72 h after 
incubation. Apoptotic nuclei were quantified by analysis of nuclear 
chromatin morphology from five fields ( 20 objective) per well. (B) 
Cells were stained with fluorescein-conjugated annexin V and with 
propidium iodide and counterstained with Hoechst 33342 at 8, 24, 
and 48 h after incubation. Apoptotic cells stained annexin V 
positive, but propidium iodide negative were quantified from three 
fields ( 20 objective) per well. In the presence of FGF-2, treatment 
with SB202190 reduced the frequency of apoptotic cells at 48 and 72 h 
but not at 8 and 24 h of incubation. Each bar shows the mean   SD 
of duplicate wells. Asterisk indicates significantly different from FGF-2 
or FGF-2   SB202474 at p   0.03 (unpaired Student’s t test). 
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control compound SB202474 did not support FGF-2–depen-
dent cell proliferation, indicating that the effect of SB202190
resulted from inhibition of p38. These data show that p38 in-
hibition in combination with FGF-2 treatment led to in-
creased DNA synthesis at 24 h treatment and a stabilization of
cell numbers during the 3 d of treatment with SB202190.
 
FGF-2 but not VEGF activates p38 in vascular 
endothelial cells in the chick embryos
 
FGF-2 treatment of the chick embryos is known to induce
angiogenesis in the chick chorioallantoic membrane (CAM).
To examine whether p38 activity was associated with growth
factor–induced angiogenesis, we measured the kinetics of p38
activation in the CAMs that were stimulated with FGF-2. In-
creased activation of p38 was detected in the CAMs 10–60
min after their exposure to FGF-2 (Fig. 8 A). Furthermore,
phosphorylated p38 was detected by anti–phospho-p38 im-
munostaining of endothelial cells in the CAM tissue at 2 h af-
ter treatment with FGF-2 (Fig. 8 B). In contrast, the immu-
noreactivity was not detected when the CAM was treated with
VEGF, although VEGF also induces neovascularization of the
CAM. These results demonstrate that FGF-2 activates p38 in
endothelial cells during angiogenesis in vivo.
 
SB202190 treatment enhances FGF-2–induced 
neovascularization but impairs neovascular 
morphogenesis in the chick embryos
 
To examine the role of p38 activation during angiogenesis,
the CAMs were treated with the p38 inhibitor SB202190
and stimulated or not with FGF-2. FGF-2 induced neovas-
cularization in the CAM (Fig. 9 A), the extent of which was
estimated by counting number of vessel branches (Fig. 9 B).
Cotreatment with FGF-2 and SB202190 but not with FGF-2
and the inactive compound SB20247, led to a significant
increase in the number of vessel branches. Treatment with
SB202190 alone had a small stimulatory effect, most likely
due to endogenous production of growth factors in the chick
embryo (Fig. 9, A and B). We next analyzed the morphology
of the vessels in the CAMs by immunostaining with an anti–
von Willebrand factor (vWF) antibody as a marker for endo-
thelial cells. Blood vessels of different diameters consisting of
monolayer of endothelial cells were visible in the CAMs
treated with FGF-2 alone (Fig. 10, left) and in the CAMs
treated with FGF-2 together with SB202474 (unpublished
data). In contrast, the CAMs treated with FGF-2 and
SB202190 displayed polymorphic microvessels with hyper-
plasia of endothelial cells (Fig. 10, right, arrowheads). The
abnormal vascular structures were frequently observed for
vessels 
 
 
 
100 
 
 
 
m in diameter. Although the abnormal vessel
lumina appeared partially or entirely closed, some of them
still contained red blood cells (Fig. 10, right, arrows), sug-
gesting that abnormal vessel structures were included in the
estimation of apparently functional vessels in CAMs treated
with FGF-2 and SB202190 shown in Fig. 9. About 50–70%
of all blood vessels stained by the anti-vWF antibody dis-
played partial or complete occlusion of the lumina in four
individual CAMs treated with FGF-2 and SB202190. These
findings indicate that activation of p38 by FGF-2 stimula-
Figure 7. SB202190 treatment leads to DNA synthesis and cell proliferation in collagen gel cultures in an FGF-2–dependent manner. 
(A and B) BCE cell collagen cultures were pretreated or not with 10  M SB202190 or 10  M SB202474 for 1 h after which time FGF-2 was 
added to 10 ng/ml. After 24 h of incubation, BrdU (10  M) was added, and after an additional 4 h of incubation the cells were fixed and 
stained with FITC-labeled anti-BrdU mAb (A, bottom). Nuclei were counterstained with Hoechst 33342 (A, middle). For comparison, cells in 
the same field were photographed in phase–contrast (A, top). BrdU-positive nuclei from five fields ( 20 objective) per well were counted, 
and the percentage of BrdU-positive nuclei among the total nuclei was calculated (B). Each bar shows the mean   SD of at least triplicate 
wells from two individual experiments. Asterisk indicates significantly different from FGF-2 or FGF-2   SB202474 at p   0.01 (unpaired 
Student’s t test). (C) BCE cell collagen cultures in 24-well dishes were pretreated or not with 10  M SB202190 or 10  M SB202474 followed 
by treatment with FGF-2 as described above. At 0, 1, 2, and 3 d of incubation, the collagen gel layers were digested with collagenase, cells 
were trypsinized, and the number of cells was determined using a Beckman Coulter counter. Similar results were obtained in two independent 
experiments. Each value is the mean   SD of triplicate wells. Asterisk indicates significantly different from FGF-2 or FGF-2   SB202474 at
p   0.04 (unpaired Student’s t test). Bars, 100  m. 
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tion is critical for formation of functional vessels in vivo by
regulation of several aspects of endothelial cell function,
such as differentiation, apoptosis, and proliferation.
 
Discussion
 
We show in this study that activation of p38 is induced by
FGF-2 in endothelial cells undergoing tubular morphogene-
sis in collagen cultures. The dramatic morphological changes
that the cell undergo accompanied by growth arrest and for-
mation of lumen are indicative of a differentiation process,
which is characterized by distinct signal transduction (Klint
and Claesson-Welsh, 1999) and gene regulatory events
(Kahn et al., 2000). Treatment with pharmacological p38
inhibitors and transient expression of dominant negative up-
stream regulators of p38 enhanced tubular morphogenesis in
an FGF-2–dependent manner by regulating differentiation,
apoptosis, and proliferation of the endothelial cells. We
could also demonstrate FGF-2–induced activation of p38 in
vivo in the chicken CAM. Inhibition of p38 augmented
 
FGF-2–induced neovascularization in the CAM, but close
inspection revealed that 
 
 
 
60% of the vessels displayed par-
tial or complete occlusion of the lumen due to hyperplasia of
the endothelial cell pool.
The mechanistic explanation for the induction of p38 ac-
tivation in the differentiating but not the proliferating endo-
thelial cells could be based on specific gene regulation, since
differentiation of endothelial cells is accompanied by induc-
tion of specific gene transcription (Kahn et al., 2000). On
the other hand, we cannot exclude that p38 activation was
dependent on the collagen matrix, since integrin signaling
pathways are known to synergize with growth factor recep-
tor pathways to regulate cell proliferation, adhesion, and mi-
gration (Clark and Brugge, 1995). The 
 
 
 
2
 
 
 
1 integrin,
which binds type 1 collagen, has been shown to mediate p38
activation in the osteosarcoma cell line Saos-2, and the sig-
nal transduction molecules Cdc42, MKK3, and MKK4
were implicated in this pathway (Ivaska et al., 1999). Activa-
tion of p38 by collagenous matrix has also been shown in
human dermal fibroblasts (Ravanti et al., 1999). These re-
sults suggest that collagen matrix–endothelial cell interac-
tion via integrins such as 
 
 
 
2
 
 
 
1 may modulate FGF-2–
induced p38 activation.
Recent studies have demonstrated that p38 activation is
required for differentiation in several different cell types in-
cluding neuronal cells (Morooka and Nishida, 1998), adipo-
cytes (Engelman et al., 1998), and myoblasts (Zetser et al.,
1999). We provide experimental evidence that activation of
p38 directly modulates endothelial cell differentiation dur-
ing tubular morphogenesis based on the following observa-
tions. First, inhibition of p38 in FGF-2–stimulated BCE
cell collagen gel cultures enhanced FGF-2–induced tubular
morphogenesis but did not affect apoptosis in the 8- and
24-h cultures (Fig. 3 B and Fig. 6). Second, treatment with
SB212190 enhanced fusion of endothelial cells, which is an
early step in the organization of the cells into tube-like struc-
tures (Fig. 5 A). Third, we found that expression of Jagged1,
a ligand for Notch family transmembrane receptors, was in-
creased during the early stage of tubular morphogenesis and
that this expression was enhanced by treatment with a p38
inhibitor (Fig. 5 B). Recent studies have shown that Notch
signaling is essential for endothelial cell differentiation dur-
ing tubular morphogenesis. Rat brain microvascular endo-
thelial cells, overexpressing Jagged1 or Notch4/int-3, a con-
stitutive active form of Notch4, form tubular structures
spontaneously (Uyttendaele et al., 2000). Targeted gene in-
activation of Jagged1 and Notch1 and double inactivation of
Notch1/Notch4 results in embryonic lethality with severe
defects in vascular remodeling (Xue et al., 1999; Krebs et al.,
2000). Expression of an activated form of Notch4 in the
mouse embryonic endothelium causes disorganization of the
vasculature and embryonic lethality (Uyttendaele et al.,
2001). Notch4 is expressed specifically in endothelial cells
during embryonic and adult life (Uyttendaele et al., 1996).
Although the specificity of Jagged1 for binding to the vari-
ous Notch receptors is still unclear, these findings imply that
the interaction of endothelial Jagged1 with Notch4 regulates
vascular morphogenesis. Our data support that induction of
Jagged1 is coupled to tubular morphogenesis and that p38
may be a potent regulator of Jagged1 expression.
Figure 8. Localization of phosphorylated p38 in FGF-2–treated 
chick embryos. (A) Activation of p38 in the CAM was analyzed after 
treatment with or without 0.5  g FGF-2 for 10–60 min and the CAM 
tissue was lysed, and p38 activity (top) and protein levels of p38 
(bottom) were measured as described in the legend to Fig. 2. (B) 
Cryosections of CAMs that had been treated with 1  g FGF-2 or 1 
 g VEGF for 2 h or untreated (Control) were examined for phos-
phorylated p38 using indirect immunofluorescence and photographed 
in phase–contrast (top) and in fluorescence view (middle). Series of 
the sections were processed for indirect immunofluorescence using 
anti–human vWF antibody to detect endothelia of vessels (bottom). 
Bars, 50  m. 
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Vascular homeostasis, which prevails, for example, in the
healthy male is thought to depend on a balance between pro-
gression and regression, regulated by the microenvironment
(Folkman and Haudenschild, 1980). Recent studies indicate
that apoptosis of the endothelium plays a central role in the
regression of the vasculature (Dimmeler and Zeiher, 2000).
Apoptosis-mediated cell deletion during tubular morpho-
genesis has been demonstrated in human umbilical vein en-
dothelial (HUVE) cells (Pollman et al., 1999) and bovine
aortic endothelial cells (Kuzuya et al., 1999). Activation of
p38 is likely to be important in the induction of apoptosis
and regression of angiogenesis in accordance with the well-
 
established notion that apoptosis induced by several stress
stimuli involves the action of p38 (Kyriakis and Avruch,
1996). In line with this view, our data showed that p38 inhi-
bition reduced the degree of apoptosis in the differentiating
primary endothelial cells (Fig. 6). Regulation of growth may
be achieved in part by induction of apoptosis/regression but
also partly by direct inhibition of cell cycle progression. The
p38 pathway has been shown to play a negative regulatory
role in cell cycle progression (Molnar et al., 1997; Takenaka
et al., 1998; Yu and Sato, 1999). Yu and Sato (Yu and Sato,
1999) reported that inhibition of p38 correlated with de-
creased expression of cdk inhibitor p27
 
Kip1
 
 and hyperphos-
Figure 9. SB202190 treatment enhances neovascu-
larization in FGF-2–treated chick embryos. (A) Angio-
genesis was examined in 10-d-old chick CAMs treated 
with PBS (Control) or 0.1  g FGF-2 in the presence or 
absence of 10  M SB202190 or 10  M SB202474. (B) 
The number of vessel branches was estimated as 
described previously (Brooks et al., 1994). Treatment 
with FGF-2 induced neovascularization in the CAMs. 
The addition of SB202190 enhanced FGF-2–induced 
neovascularization, whereas the addition of SB202474 
had no effect. Similar results were obtained in three 
independent experiments. Each bar shows the mean   
SD from five to seven embryos. Asterisk indicates sig-
nificantly different from FGF-2 at p   0.04 (Mann-
Whitney’s U test).
Figure 10. SB202190 treatment impairs vascular morphogenesis in FGF-2–treated chick embryos. Sections of CAMs that had been treated 
with 0.1  g FGF-2 in the presence or absence of 10  M SB202190 were examined immunohistochemically using an anti–human vWF antibody 
to detect endothelial cells. Cotreatment with FGF-2 and SB202190 induced hyperplasia of endothelial cells and abnormal vascular morphologies 
(arrowheads). Erythrocytes (arrows) were visible in a vessel with partially occluded lumen. Bars: (FGF-2 and FGF-2   SB202190) 50  m; 
(inset) 10  m. 
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phorylation of the Rb tumor suppressor protein in HUVE
cells. Therefore, growth arrest of endothelial cells during tu-
bular morphogenesis may be mediated via a p38-mediated
block in cell cycle progression (Fig. 7, A and B).
Gene inactivation of upstream regulators of p38 or indi-
vidual p38 isoforms has demonstrated a role for the p38
pathway in vascular development and regulation of angio-
genesis. Disruption of the p38
 
 
 
 gene results in embryonic
lethality around E12.5 due to severe defects in placental de-
velopment (Adams et al., 2000; Mudgett et al., 2000;
Tamura et al., 2000). The p38
 
 
 
-null placentas display a se-
vere reduction in the labyrinthine layer and lack of intermin-
gling embryonic and maternal blood vessels, consistent with
a defect in vascularization. The p38
 
 
 
-null mice also display
defects in cardiovascularization. However, this defect is
likely to be secondary to the impairment in placental func-
tion (Adams et al., 2000). A similar phenotype with vascular
defects in the placenta was noted in mice lacking expression
of MEKK3, a p38 MAPK kinase kinase (Yang et al., 2000).
On the other hand, inactivation of MKK3, a p38 MAPK ki-
nase, did not reveal vascular abnormalities (Lu et al., 1999),
indicating the complexity of the p38 pathway. Several differ-
ent downstream targets of p38 have been identified, includ-
ing protein kinases such as MAPK-activated protein kinase-
2/3 and transcription factors such as ATF-2, Elk-1, CHOP,
and myocyte enhance factor (MEF)2C (Ono and Han,
2000). For example, MEF2C is expressed in endothelial cells
in the embryo and plays a crucial role in cardiovascular de-
velopment (Lin et al., 1997, 1998). In embryos lacking ex-
pression of MEF2C, endothelial cells fail to organize prop-
erly and form vascular anomalies characterized by extreme
variability in lumen size and defects in remodeling. Thus,
MEF2C may be involved downstream of the p38-dependent
signaling pathway for regulating vascular morphogenesis.
In the present study, treatment with the p38 inhibitor–
enhanced FGF-2 induced the CAM neovascularization, but
 
 
 
60% of the vessels displayed features indicative of hyper-
plasia of the endothelial cells with partially or completely
closed lumen. These in vivo results correlate with the in
vitro data, since the p38 inhibitor treatment induced cell
proliferation and survival in BCE cells collagen gel culture.
The morphological features of the vascular defect in p38
 
 
 
-
null placentas are different from that in the CAMs treated
with the p38 inhibitor. The cellular response to p38 activa-
tion may be dependent on the expression pattern of the p38
isoforms and the stimulating agent. Placentas express high
level of p38
 
 
 
 and p38
 
  
 
but not p38
 
 
 
 and p38
 
 
 
 (Wang et
al., 1997), whereas vascular endothelial cells coexpress p38
 
 
 
,
p38
 
 
 
, and p38
 
 
 
 (Hale et al., 1999). VEGF and placenta
growth factor, which are implicated as major regulators of
placenta angiogenesis, also activate p38 (Rousseau et al.,
1997; Desai et al., 1999). Interestingly, VEGF-induced p38
activity has been shown to positively regulate migration and
actin reorganization in HUVE cells (Rousseau et al., 1997).
In this study, activation of p38 by VEGF was weaker and
more transient in the differentiating primary microcapillary
endothelial cell compared with treatment with FGF-2.
In conclusion, our data indicate that FGF-2–stimulated
p38 signaling pathway has a critical role during angiogenesis
in negative regulation of different aspects of endothelial cell
function. This regulation may be required for the normal as-
sembly of endothelial cells during vascular morphogenesis
and the maintenance of established vessels.
 
Materials and methods
 
Tissue culture
 
BCE cells were isolated from calf adrenal cortex as described (Qi et al.,
1999) and used at passage 10–14. For routine culture, the cells were cul-
tured in DME (Life Technologies), 10% newborn calf serum (NCS), 2 ng/ml
FGF-2 (Boehringer) on gelatinized dishes. For collagen gel cultures, col-
lagen type I (Vitrogen; Cohesion Technologies, Inc.) was mixed with 10
 
 
 
Ham’s F12 medium and 0.1 M NaOH (8:1:1) distributed in dishes or onto
glass coverslips in 6-well plates and allowed to gel at 37
 
 
 
C overnight.
When indicated, cells were starved in DME, 1% NCS for 16 h.
 
p38 assays
 
Serum-starved BCE cells were untreated or treated with 50 ng/ml FGF-2 or
100 ng/ml VEGF (Peprotech) for 5–60 min or with 300 mM NaCl for 30
min. Alternatively, BCE cells were seeded on collagen gels, incubated for 8
h, and then serum starved and stimulated. Cells were lysed in a Triton X-
100 containing phosphatase and protease inhibitors, and immunoprecipi-
tation was performed using an anti-p38 antibody (Gerwins et al., 1997).
Samples were washed in kinase buffer (20 mM Hepes, pH 8.0, 20 mM
MgCl
 
2
 
, 2 mM MnCl
 
2
 
, 1 mM DTT) and incubated for 30 min at 30
 
 
 
C in ki-
nase buffer, 5 
 
 
 
Ci of [
 
 
 
-
 
32
 
P]ATP (Amersham Pharmacia Biotech), and 5 
 
 
 
g
recombinant NH
 
2
 
-terminal fragment of ATF-2. Samples were resolved by
SDS-PAGE in 12% gels and analyzed using a Bio-Imager BAS-1800II (Fuji).
For in vitro kinase inhibition assays, p38 was immunoprecipitated
and preincubated or not with 10 
 
 
 
M SB202190 (Calbiochem-Novabio-
chem), a specific inhibitor of p38, or 10 
 
 
 
M SB202474 (Calbiochem-
Novabiochem), an inactive compound, before the kinase assay. The p38
assays in the CAM was performed essentially according to Eliceiri et al.
(1998). Briefly, 0.8 
 
 
 
 0.8 cm filter disks (Whatman) were saturated with
3 mg/ml cortisone acetate (Sigma-Aldrich) and soaked in PBS (40 
 
 
 
l for
each filter) with or without FGF-2 (0.5 
 
 
 
g for each filter) on the CAMs.
CAM tissue was harvested, snap frozen, and homogenized in a modified
RIPA buffer containing 1% deoxycholic acid, 1% Triton X-100, and
0.1% SDS. Equivalent amounts (700 
 
 
 
g) of protein were analyzed as de-
scribed above.
 
Tube formation assay
 
Serum-starved BCE cells were inoculated onto the collagen gels in 6-well
dishes at 5 
 
 
 
 10
 
4
 
 cells/cm
 
2
 
 and incubated for 3 h at 37
 
 
 
C, and then a sec-
ond layer of collagen was added. After gelling, cultures were treated with
or without 10 ng/ml FGF-2 in DME, 1% NCS. In indicated experiments,
SB202190, SB202474, or 0.1% DMSO was added to cells 1 h before addi-
tion of FGF-2. The cultures were incubated for 72 h without readdition of
growth factors or inhibitors. The cells were examined using a phase–con-
trast microscope (Nikon Eclipse TE 300) at indicated time points. To quan-
tify the length of tubular structures, three random phase–contrast photomi-
crographs (
 
 
 
10 objective) per well were taken, and the tubule length was
measured using NIH image software (version 1.56). Tubes shorter than 100
 
 
 
m were excluded from the measurements.
 
Detection of apoptotic cells
 
BCE cells treated or not with 10 ng/ml FGF-2 and 10 
 
 
 
M SB202190 or 10 
 
 
 
M
SB202474 were fixed in 3% paraformaldehyde (Sigma-Aldrich) in PBS and
stained with 5 
 
 
 
g/ml Hoechst 33342 (Molecular Probes) for 30 min. Nuclei
with condensed chromatin and fragmented nuclei from five fields (
 
 
 
20 objec-
tive) per well were counted. For early detection of apoptosis, BCE cells were
stained with fluorescein-conjugated annexin V using Annexin-V-FLUOS stain-
ing kit (Roche Molecular Biochemicals). Nuclei were counterstained with 5
 
 
 
g/ml Hoechst 33342, and the number of annexin V–positive cells was
counted from three fields (
 
 
 
20 objective) per well. Necrotic cells identified
through propidium iodide were excluded from the estimation.
 
Plasmid constructions and transient transfections
 
Human cDNAs encoding MKK3 (sequence data available from GenBank/
EMBL/DDBJ under accession no. L36719) and MKK6 (sequence data avail-
able from GenBank/EMBL/DDBJ under accession no. U39657) were gen-
erated by PCR from HL60 cells using primers where the 5
 
 
 
 primer con-
tained the HA tag sequence YPYDVPDYA. The dominant negative versions
of MKK3 and MKK6 (Raingeaud et al., 1996) were created by site-directed 
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mutagenesis where S189/T193 in MKK3 and S207/T211 in MKK6 were
changed to alanines. All constructs were verified by DNA sequencing.
Transient transfections of BCE cells with the different constructs were per-
formed using LipofectAMINE™ (Life Technologies).
 
Cell proliferation assay
 
Serum-starved BCE cells were seeded at 9 
 
 
 
 10
 
4
 
 cells/well on collagen
gel–containing 24-well plates. After 3 h, cells were stimulated with 10 ng/
ml FGF-2. In indicated experiments, 10 
 
 
 
M SB202190, 10 
 
 
 
M SB202474,
or 0.1% DMSO was added to cells 1 h before addition of FGF-2. At indi-
cated time points, the gel was solubilized with 20 
 
 
 
l collagenase (2.5 U/
 
 
 
l
in PBS; Sigma-Aldrich) for 2 h at 37
 
 
 
C, after which time 230 
 
 
 
l trypsin/
EDTA per well was added. Changes in the cell count were determined
with a Beckman Coulter counter.
 
Detection of S-phase cells
 
Serum-starved BCE cells were inoculated onto collagen gel–containing
coverslips at a density of 10
 
5
 
 cells/cm
 
2
 
 and incubated at 37
 
 
 
C for 2 h. Cul-
tures were treated with 10 
 
 
 
M SB202190, 10 
 
 
 
M SB202474, or 0.1%
DMSO for 1 h followed by addition of 10 ng/ml FGF-2. After 24 h incuba-
tion at 37
 
 
 
C, 10 
 
 
 
M BrdU (Sigma-Aldrich) was added, and incubation con-
tinued for 4 h. Cells were fixed in 70% ethanol for 30 min, washed with
PBS, and incubated in 0.02 M NaOH for 2 min followed by five washes
with PBS. FITC-conjugated anti-BrdU mAb (2:5 dilution; Becton Dickin-
son) was added, and after 1 h the cells were stained with 5 
 
 
 
g/ml Hoechst
33342 for counter staining of whole nuclei. The labeling index was ex-
pressed as the percentage of labeled nuclei/total nuclei from five fields
(
 
 
 
20 objective) per well.
 
Immunoblotting
 
Serum-starved BCE cells were pretreated for 1 h with 10 
 
 
 
M SB202190 or
0.1% DMSO and then treated with 10 ng/ml FGF-2. The cells were lysed
in 500 
 
 
 
l boiling SDS sample buffer at the indicated time points, and sam-
ples were analyzed by SDS-PAGE and immunoblotting using nitrocellu-
lose filter (Hybond-ECL; Amersham Pharmacia Biotech). The blots were
incubated with anti-Jagged1 antibody (1:200 dilution; Santa Cruz
Biotechnology, Inc.) overnight at 4
 
 
 
C, washed, and then incubated with
HRP-conjugated anti–rabbit Ig antibody (1:2,500 dilution; Amersham
Pharmacia Biotech) followed by ECL detection (Amersham Pharmacia Bio-
tech). For immunoblotting of p38 and HA-tagged constructs, one part of
the cell lysates (80 
 
 
 
l) was separated by SDS-PAGE, transferred, and
probed with anti-p38 antibody (1:1,000 dilution) or anti-HA mAb (1:1,000
dilution; Boehringer).
 
Angiogenesis assay in chicken embryos
 
The angiogenesis assay in the CAM was performed as described (Sasaki et
al., 1999) using fertilized 10-d chick eggs in which the CAM was exposed
by removing a 1 
 
 
 
 1 cm piece of the shell to allow application of What-
man filter disks saturated with 3 mg/ml cortisone acetate soaked in PBS (50
 
 
 
l for each filter) with or without FGF-2 (0.1 
 
 
 
g for each filter) and 10 
 
 
 
M
SB202190 or 10 
 
 
 
M SB202474. After 3 d of incubation, the CAM was cut
around the filter and inspected in a double-blind procedure to determine
the number of vessel branches in the area of the filter disk as described
previously (Brooks et al., 1994).
 
Immunohistochemistry and immunofluorescence
 
For immunohistochemical analysis of endothelia in the CAM, treated CAM
fragments were fixed with formalin and embedded in paraffin. Paraffin-
embedded sections were deparaffinized and incubated with anti–human
vWF antibody (1:100 dilution; Dako) followed by biotinylated anti–rabbit Ig
(1:100 dilution; Dako). A positive reaction was detected by the ABC method
(Dako) and visualized by the DAB reaction. Sections were counterstained
with hematoxylin.
Immunofluorescence analysis of phosphorylated p38 in the CAM was
performed essentially as described previously (Eliceiri et al., 1998). Treated
CAM fragments were embedded in Tissue-Tek OCT compound (Sakura
Fintek), frozen, and 4-
 
 
 
m cryostat sections were cut, fixed in acetone for
15 min, blocked in 1% BSA in PBS, incubated with anti–phospho-p38 an-
tibody (1:50 dilution) or anti–human vWF antibody (1:100 dilution) over-
night, washed, and incubated with TRITC-conjugated goat anti–rabbit IgG
(1:50 dilution; Zymed Laboratories) for 30 min.
 
Statistical analysis
 
Results are expressed as mean 
 
 
 
 SD. Statistical analyses were performed
using StatView software (Version 4.5; SAS Institute, Inc.). Student’s 
 
t
 
 test
and Mann-Whitney’s U test were used for intergroup comparisons.
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